Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol

Burry KA, K A Burry, Kenneth A. Burry, P E Patton, Phillip E. Patton, Patton PE, Illingworth DR, D R Illingworth, D. Roger Illingworth
American Journal of Obstetrics and Gynecology · 1989 · vol. 160(6) , pp. 1454–1461 · doi:10.1016/0002-9378(89)90870-3 · PMID:2525337 · W2066515003
article OA: closed CC0 ⤵ 27 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated metabolic differences in women with endometriosis treated with nafarelin acetate versus danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In this double-blind study of changes in plasma lipid and lipoprotein concentrations during 6-month medical treatment of endometriosis, 53 patients were randomly assigned to one of four treatment schedules: danazol, 800 mg/day (n = 10); danazol, 600 mg/day (n = 8); intranasal nafarelin acetate, 800 micrograms/day (n = 10); or intranasal nafarelin acetate, 400 micrograms/day (n = 25). Plasma levels of triglycerides, cholesterol, and low-density lipoprotein, very low-density lipoprotein, and high-density lipoprotein cholesterol fractions were obtained before, during, and 1 month after treatment. High-density lipoprotein2 and high-density lipoprotein3 cholesterol concentrations were measured in selected patients. Body weight was also followed. The drugs were equally effective in achieving symptomatic relief and laparoscopically demonstrated resolution of endometriosis but differed significantly in their effects on lipid concentrations. Nafarelin acetate had no adverse effects on serum lipoprotein concentrations, whereas danazol significantly decreased high-density lipoprotein cholesterol (p less than 0.01), as well as the high-density lipoprotein2 subfraction (p less than 0.05), and increased low-density lipoprotein cholesterol (p less than 0.01). Danazol significantly increased body weight (p less than 0.01), whereas nafarelin did not.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Genital Neoplasms, Female Gonadotropin-Releasing Hormone Lipids Pregnadienes Administration, Intranasal Adult Cholesterol Cholesterol Clinical Trials as Topic Danazol Danazol Double-Blind Method Endometriosis Endometriosis Endometriosis Female Genital Neoplasms, Female Genital Neoplasms, Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (27)

Source provenance

europepmc
last seen: 2026-07-25T06:15:30.875455+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
License: CC0 · commercial use OK